Used in research for the treatment of acute myeloid leukemia (AML), particularly in cases involving mutations in the IDH1 gene. It functions as an inhibitor of the mutant IDH1 enzyme, which is responsible for abnormal cell differentiation in leukemia. By blocking this enzyme, the compound helps restore normal blood cell development and reduce the proliferation of cancerous cells. Currently under investigation in clinical trials to evaluate its efficacy, safety, and optimal dosing in patients with relapsed or refractory AML.